vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and MODIV INDUSTRIAL, INC. (MDV). Click either name above to swap in a different company.
MODIV INDUSTRIAL, INC. is the larger business by last-quarter revenue ($11.1M vs $10.7M, roughly 1.0× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 11.0%, a 12.5% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs -5.6%). Over the past eight quarters, MODIV INDUSTRIAL, INC.'s revenue compounded faster (-3.8% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.
ABUS vs MDV — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $11.1M |
| Net Profit | $2.5M | $1.2M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 45.8% |
| Net Margin | 23.5% | 11.0% |
| Revenue YoY | 522.2% | -5.6% |
| Net Profit YoY | 112.7% | -22.0% |
| EPS (diluted) | $0.01 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $11.7M | ||
| Q2 25 | $10.7M | $11.8M | ||
| Q1 25 | — | $11.8M | ||
| Q4 24 | — | $11.7M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | — | $11.4M | ||
| Q1 24 | — | $12.0M |
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $1.0M | ||
| Q2 25 | $2.5M | $-2.0M | ||
| Q1 25 | — | $829.0K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $-587.0K | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $3.7M |
| Q4 25 | — | 45.8% | ||
| Q3 25 | — | 41.4% | ||
| Q2 25 | 13.9% | 9.8% | ||
| Q1 25 | — | 40.2% | ||
| Q4 24 | — | 45.4% | ||
| Q3 24 | — | 42.0% | ||
| Q2 24 | — | 44.6% | ||
| Q1 24 | — | 55.6% |
| Q4 25 | — | 11.0% | ||
| Q3 25 | — | 9.0% | ||
| Q2 25 | 23.5% | -17.1% | ||
| Q1 25 | — | 7.0% | ||
| Q4 24 | — | 13.3% | ||
| Q3 24 | — | -5.0% | ||
| Q2 24 | — | 11.6% | ||
| Q1 24 | — | 31.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | $0.01 | $-0.32 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $14.4M |
| Total DebtLower is stronger | $0 | $261.5M |
| Stockholders' EquityBook value | $83.0M | $162.7M |
| Total Assets | $103.3M | $476.5M |
| Debt / EquityLower = less leverage | 0.00× | 1.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $8.3M | ||
| Q2 25 | $37.4M | $5.8M | ||
| Q1 25 | — | $6.2M | ||
| Q4 24 | — | $11.5M | ||
| Q3 24 | — | $6.8M | ||
| Q2 24 | — | $18.9M | ||
| Q1 24 | — | $18.4M |
| Q4 25 | — | $261.5M | ||
| Q3 25 | — | $279.7M | ||
| Q2 25 | $0 | $279.7M | ||
| Q1 25 | — | $279.7M | ||
| Q4 24 | — | $279.8M | ||
| Q3 24 | — | $279.7M | ||
| Q2 24 | — | $279.7M | ||
| Q1 24 | — | $279.6M |
| Q4 25 | — | $162.7M | ||
| Q3 25 | — | $164.8M | ||
| Q2 25 | $83.0M | $165.6M | ||
| Q1 25 | — | $171.1M | ||
| Q4 24 | — | $190.1M | ||
| Q3 24 | — | $186.3M | ||
| Q2 24 | — | $187.0M | ||
| Q1 24 | — | $188.0M |
| Q4 25 | — | $476.5M | ||
| Q3 25 | — | $499.6M | ||
| Q2 25 | $103.3M | $498.9M | ||
| Q1 25 | — | $506.8M | ||
| Q4 24 | — | $507.8M | ||
| Q3 24 | — | $507.4M | ||
| Q2 24 | — | $519.5M | ||
| Q1 24 | — | $522.5M |
| Q4 25 | — | 1.61× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | 0.00× | 1.69× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | 1.50× | ||
| Q1 24 | — | 1.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $15.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | -6.24× | 12.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $4.1M | ||
| Q2 25 | $-15.7M | $3.9M | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | — | $18.2M | ||
| Q3 24 | — | $5.1M | ||
| Q2 24 | — | $4.7M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 12.34× | ||
| Q3 25 | — | 3.95× | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | 3.68× | ||
| Q4 24 | — | 11.72× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.55× | ||
| Q1 24 | — | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
